These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 12919697)

  • 1. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.
    Bendre MS; Montague DC; Peery T; Akel NS; Gaddy D; Suva LJ
    Bone; 2003 Jul; 33(1):28-37. PubMed ID: 12919697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis.
    Sabokbar A; Kudo O; Athanasou NA
    J Orthop Res; 2003 Jan; 21(1):73-80. PubMed ID: 12507582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
    Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
    J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
    Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
    Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
    Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer metastasis to bone: it is not all about PTHrP.
    Bendre M; Gaddy D; Nicholas RW; Suva LJ
    Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S39-45. PubMed ID: 14600591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis.
    Romas E; Gillespie MT; Martin TJ
    Bone; 2002 Feb; 30(2):340-6. PubMed ID: 11856640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.
    Atkins GJ; Bouralexis S; Haynes DR; Graves SE; Geary SM; Evdokiou A; Zannettino AC; Hay S; Findlay DM
    Bone; 2001 Apr; 28(4):370-7. PubMed ID: 11336917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
    Kitazawa S; Kitazawa R
    J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
    Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
    PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein.
    Kuo PL; Liao SH; Hung JY; Huang MS; Hsu YL
    Biochim Biophys Acta; 2013 Jun; 1830(6):3756-66. PubMed ID: 23458685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone.
    Faucheux C; Horton MA; Price JS
    J Bone Miner Res; 2002 Mar; 17(3):455-64. PubMed ID: 11874237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue.
    Ogasawara T; Yoshimine Y; Kiyoshima T; Kobayashi I; Matsuo K; Akamine A; Sakai H
    J Periodontal Res; 2004 Feb; 39(1):42-9. PubMed ID: 14687227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.